ProKidney Corp
PROK2.710USD
+0.180+7.11%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
361.57MMarket Cap
LossP/E TTM
More Details of ProKidney Corp Company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Company Info
Ticker SymbolPROK
Company nameProKidney Corp
IPO dateJun 30, 2021
CEODr. Bruce Culleton, M.D.
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd.
CityWINSTON-SALEM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEODr. Bruce Culleton, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Lucio Tozzi
Mr. Lucio Tozzi
Senior Vice President - Global Clinical Operations
Senior Vice President - Global Clinical Operations
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Other
59.39%
Shareholders
Shareholders
Proportion
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Other
59.39%
Shareholder Types
Shareholders
Proportion
Corporation
24.70%
Investment Advisor
10.51%
Hedge Fund
10.27%
Investment Advisor/Hedge Fund
5.98%
Research Firm
2.88%
Individual Investor
1.92%
Endowment Fund
0.74%
Family Office
0.04%
Bank and Trust
0.04%
Other
42.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
2023Q1
183
53.54M
87.01%
-23.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tolerantia LLC
22.62M
17.46%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.53%
--
--
Mar 31, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
8.28%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
10.04M
7.75%
-3.51M
-25.90%
Mar 31, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.65%
--
--
Mar 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.89%
--
--
May 31, 2025
Bleichroeder LP
2.00M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
4.88%
+8.24K
+0.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.21M
4.02%
-63.88K
-1.21%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
